JP2021530543A - アルツハイマー病を処置するためのリルゾールプロドラッグの使用 - Google Patents

アルツハイマー病を処置するためのリルゾールプロドラッグの使用 Download PDF

Info

Publication number
JP2021530543A
JP2021530543A JP2021503571A JP2021503571A JP2021530543A JP 2021530543 A JP2021530543 A JP 2021530543A JP 2021503571 A JP2021503571 A JP 2021503571A JP 2021503571 A JP2021503571 A JP 2021503571A JP 2021530543 A JP2021530543 A JP 2021530543A
Authority
JP
Japan
Prior art keywords
patient
administered
riluzole
disease
riluzole prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021503571A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020023324A5 (https=
JP2021530543A5 (https=
Inventor
ブラディミア・コリック
ロバート・バーマン
イルファン・クレシ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Therapeutics Ltd
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of JP2021530543A publication Critical patent/JP2021530543A/ja
Publication of JPWO2020023324A5 publication Critical patent/JPWO2020023324A5/ja
Publication of JP2021530543A5 publication Critical patent/JP2021530543A5/ja
Priority to JP2025026643A priority Critical patent/JP2025093952A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021503571A 2018-07-22 2019-07-20 アルツハイマー病を処置するためのリルゾールプロドラッグの使用 Pending JP2021530543A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025026643A JP2025093952A (ja) 2018-07-22 2025-02-21 アルツハイマー病を処置するためのリルゾールプロドラッグの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701814P 2018-07-22 2018-07-22
US62/701,814 2018-07-22
PCT/US2019/042718 WO2020023324A1 (en) 2018-07-22 2019-07-20 Use of riluzole prodrugs to treat alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025026643A Division JP2025093952A (ja) 2018-07-22 2025-02-21 アルツハイマー病を処置するためのリルゾールプロドラッグの使用

Publications (3)

Publication Number Publication Date
JP2021530543A true JP2021530543A (ja) 2021-11-11
JPWO2020023324A5 JPWO2020023324A5 (https=) 2022-02-15
JP2021530543A5 JP2021530543A5 (https=) 2022-02-15

Family

ID=69181140

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021503571A Pending JP2021530543A (ja) 2018-07-22 2019-07-20 アルツハイマー病を処置するためのリルゾールプロドラッグの使用
JP2025026643A Pending JP2025093952A (ja) 2018-07-22 2025-02-21 アルツハイマー病を処置するためのリルゾールプロドラッグの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025026643A Pending JP2025093952A (ja) 2018-07-22 2025-02-21 アルツハイマー病を処置するためのリルゾールプロドラッグの使用

Country Status (15)

Country Link
US (1) US12161633B2 (https=)
EP (1) EP3823616A4 (https=)
JP (2) JP2021530543A (https=)
KR (1) KR20210034621A (https=)
CN (1) CN112469408A (https=)
AU (1) AU2019310013B2 (https=)
BR (1) BR112021000768A2 (https=)
CA (1) CA3107215A1 (https=)
EA (1) EA202190308A1 (https=)
IL (1) IL280177B2 (https=)
MX (2) MX2021000515A (https=)
NZ (1) NZ772009A (https=)
PH (1) PH12021550043A1 (https=)
SG (1) SG11202100385YA (https=)
WO (1) WO2020023324A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230027189A (ko) * 2020-06-24 2023-02-27 바이오하벤 테라퓨틱스 리미티드 강박 장애를 치료하기 위한 조성물 및 방법
EP4240308A4 (en) * 2020-10-05 2024-10-30 Icahn School of Medicine at Mount Sinai Riluzole for the treatment of alzheimer's disease
EP4277624B1 (en) * 2021-01-18 2026-01-14 Biohaven Therapeutics Ltd. Troriluzole for use in the treatment of alzheimer's disease of mild severity
WO2022178425A1 (en) * 2021-02-22 2022-08-25 Yale University Targeted bifunctional degraders
CN114344297B (zh) * 2022-03-01 2024-05-14 暨南大学 利鲁唑在治疗少精症中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004501875A (ja) * 2000-06-14 2004-01-22 メダレックス，インコーポレイティド トリペプチドプロドラッグ化合物
JP2008518935A (ja) * 2004-11-01 2008-06-05 セオ ホン ユー 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
WO2017201502A1 (en) * 2016-05-20 2017-11-23 Biohaven Pharmaceutical Holding Company Ltd. Use of glutamate modulating agents with immunotherapies to treat cancer
JP2017535569A (ja) * 2014-11-26 2017-11-30 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． イブジラスト及びリルゾールの併用及びその使用法
JP2018508525A (ja) * 2015-03-03 2018-03-29 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． リルゾールプロドラッグおよびそれらの使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2957077B1 (fr) * 2010-03-02 2012-04-13 Univ Dauvergne Clermont I Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
EP3079692A4 (en) 2013-12-09 2017-10-18 Thomas Jefferson University Novel methods of treating a neurodegenerative disease in a mammal in need thereof
WO2018031707A1 (en) * 2016-08-10 2018-02-15 Biohaven Pharmaceutical Holding Company Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
AU2019223014B2 (en) * 2018-02-21 2024-10-17 Orphai Therapeutics Inc. Combination therapy with apilimod and glutamatergic agents
EP4277624B1 (en) * 2021-01-18 2026-01-14 Biohaven Therapeutics Ltd. Troriluzole for use in the treatment of alzheimer's disease of mild severity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004501875A (ja) * 2000-06-14 2004-01-22 メダレックス，インコーポレイティド トリペプチドプロドラッグ化合物
JP2008518935A (ja) * 2004-11-01 2008-06-05 セオ ホン ユー 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
JP2017535569A (ja) * 2014-11-26 2017-11-30 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． イブジラスト及びリルゾールの併用及びその使用法
JP2018508525A (ja) * 2015-03-03 2018-03-29 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． リルゾールプロドラッグおよびそれらの使用
WO2017201502A1 (en) * 2016-05-20 2017-11-23 Biohaven Pharmaceutical Holding Company Ltd. Use of glutamate modulating agents with immunotherapies to treat cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS.GOV ARCHIVE NCT03605667, JPN6022050265, 27 July 2018 (2018-07-27), ISSN: 0005264655 *
JOURNAL OF BIOMEDICAL SCIENCE, vol. 24, JPN6024006715, 2017, pages 1 - 12, ISSN: 0005442229 *
JOURNAL OF NEUROCHEM., vol. 135, JPN6024006714, 2015, pages 207 - 209, ISSN: 0005442228 *
JOURNAL OF PREVENTION OF ALZHEIMER'S DISEASE, vol. 5, no. 1, JPN6023026339, October 2018 (2018-10-01), pages 148 - 149, ISSN: 0005264656 *
PNAS, vol. 111(52), JPN6024006713, 2014, pages 18733 - 18738, ISSN: 0005442227 *

Also Published As

Publication number Publication date
CN112469408A (zh) 2021-03-09
EP3823616A1 (en) 2021-05-26
US20210290599A1 (en) 2021-09-23
SG11202100385YA (en) 2021-02-25
EA202190308A1 (ru) 2021-05-19
BR112021000768A2 (pt) 2021-05-11
NZ772009A (en) 2026-02-27
WO2020023324A1 (en) 2020-01-30
IL280177A (en) 2021-03-01
EP3823616A4 (en) 2022-05-04
IL280177B1 (en) 2024-09-01
IL280177B2 (en) 2025-01-01
MX2021000515A (es) 2021-06-08
US12161633B2 (en) 2024-12-10
KR20210034621A (ko) 2021-03-30
CA3107215A1 (en) 2020-01-30
PH12021550043A1 (en) 2021-09-20
AU2019310013A1 (en) 2021-02-11
AU2019310013B2 (en) 2025-01-02
JP2025093952A (ja) 2025-06-24
MX2024010655A (es) 2024-09-11

Similar Documents

Publication Publication Date Title
JP2021530543A (ja) アルツハイマー病を処置するためのリルゾールプロドラッグの使用
TWI595875B (zh) 用於治療阿茲海默症之方法及藥物產品
US11123332B2 (en) Gaboxadol for reducing risk of suicide and rapid relief of depression
JP2017061482A (ja) ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療
JP2017222691A (ja) 多発性硬化症を治療するための高投与量ラキニモドの使用
US20100178362A1 (en) Chromium complexes for improvement of memory and cognitive function
JP2020186274A (ja) レベチラセタムの持続放出性医薬組成物
JP7352542B2 (ja) 運動失調を処置するためのリルゾールプロドラッグの使用
TW202339763A (zh) 用於治療多種疾病之組成物及方法
EP4277624B1 (en) Troriluzole for use in the treatment of alzheimer's disease of mild severity
US12201618B2 (en) Use of riluzole prodrugs to treat Alzheimer's disease
CN112822997A (zh) 用于治疗孤独症的组合物和方法
EA049330B1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
US20250275953A1 (en) Vodobatinib for reducing progression of parkinson's disease
WO2025194109A1 (en) Compositions and methods for improving brain function
Viña et al. Genistein effect on cognition in early Alzheimer’s disease patients. The GENIAL clinical trial
WO2024137478A1 (en) Methods for treating various conditions and indications with agonists and antagonists
Bhattacharyya et al. P0361-Delta-9-tetrahydrocannabinol modulates parahippocampal and ventral striatal activity during processing of verbal memory
Wilson et al. Effects of marijuana on brain: Function and structure
Tariot P. 4.017 Memantine/donepezil dual-therapy is superior to placebo/donepezil therapy for treatment of moderate to severe Alzheimer's disease
Ferguson Reports on Venlafaxine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240515

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241022